AXSM News and Press, Axsome Therapeutics Inc. From 09/17/22

Biotech companies with few products on the market and red ink on the bottom line may not look like the most attractive investments right now. Equity markets are still down substantially year-to-date, and in this environment investors prefer putting their money in safer stocks. But for t...

Concerns about higher inflation and economic growth have weighed on investors' minds this year. But Axsome Therapeutics (NASDAQ: AXSM) has been defying the bear market. The biotech company's shares have climbed nearly 170% over the past three months. The excitement stems from so...

Summary For over a year, Axsome Therapeutics suffered substantial share price depreciation due to the uncertain fate of its lead medicine (AXS05). Like the cream that always rises to the top, AXS05 recently gained FDA approval for major depressive disorder which catapulted share p...

Major indexes have carried many top stocks lower this year. As the bear market emerged, even some of the healthiest companies saw their shares drop or stagnate. This presented a buying opportunity for long-term investors. But there's another potential buying opportunity out there, and that'...

NEW YORK, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executi...

The biotech sector has had a challenging year so far. The SPDR S&P Biotech ETF is still down more than 26%, and the iShares Biotechnology ETF is down more than 19%, even though both have rallied a bit in the past few months. Contrast that with Vertex Pharmaceuticals (N...

With the market dropping by more than 17% so far this year and the industry-tracking SPDR S&P Biotech ETF down by a brutal 27%, it's safe to say that conditions are looking quite bearish at the moment. Thanks to the Federal Reserve's mission to control inflation by hiking interest r...

NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced that it has enrolled the first patient in the ADVANCE-2 trial ...

NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the publication of a post-hoc analysis comparing the eff...

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executi...